MIT News
November 19, 2024
Residual cancer cells can lead to costly and invasive additional treatments, drive disease relapse and progression, and worsen patient quality of life and survival. Lumicell has developed a cost effective, real-time imaging system for eliminating even single residual cancer cells during surgery and will greatly improve patient outcomes. Piloted with seed funding from the Koch Institute Frontier Research Program, the technology was FDA-approved earlier this year.
Developed by a multidisciplinary team with an entrepreneurial bent—including Professors Linda Griffith and 2023 Nobel laureate Moungi Bawendi, Jacks lab postdoc alum David Kirsch, and staff alum W. David Lee, '69, SM '70—the system was inspired by the investigators’ personal experiences of cancer and commitment to solving real problems for real people. Hear the team behind the technology recount their journey from Frontier through FDA and share their inspiration.
Join us December 3 for “Lights Camera Action: A Close-up Take on Improving Cancer Patient Outcomes with Lumicell,” and hear the team behind the groundbreaking technology recount their journey from Frontier through FDA and share their inspiration.